LLM-powered prostate cancer staging from PSMA-PET/CT reports using PROMISE v2 - PubMed
4 hours ago
- #LLM
- #Prostate Cancer
- #PSMA-PET/CT
- LLM-powered prostate cancer staging from PSMA-PET/CT reports using PROMISE v2.
- Study conducted in accordance with the Declaration of Helsinki and approved by the institutional review board of the Technical University of Munich.
- Ethics approval reference number: 87/18S; written informed consent waived due to retrospective nature.
- Conflict of interest: ME reports fees from various pharmaceutical companies and a patent application for rhPSMA.
- Other authors report no conflict of interest.
- References include recent studies and guidelines on prostate cancer epidemiology, diagnosis, and treatment.